Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Fig. 3

Forest plots of the pooled HRs for the OS of the patients with MM in the MAbs targeting CD38 (including daratumumab) and SLAMF7 (including elotuzumab) groups versus their corresponding control groups. The HR < 1 favours the MAb group. The size of the blocks or diamonds represents the weight of the fixed effects model in the meta-analysis

Back to article page